Ipilimumab/nivolumabImmune-mediated colitis : case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1885卷 / 1期

关键词：

D O I：

10.1007/s40278-021-07040-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：281 / 281

相关论文

共 50 条

[21] Ipilimumab/nivolumabImmune-mediated hypothyroidism and immune-mediated hypophysitis: case report
Reactions Weekly, 2023, 1969 (1) : 201 - 201
[22] NivolumabImmune-mediated hepatitis: case report
Reactions Weekly, 2017, 1658 (1) : 353 - 353
[23] NivolumabImmune-mediated myocarditis: case report
Reactions Weekly, 2021, 1875 (1) : 265 - 265
[24] NivolumabImmune-mediated pneumonitis: case report
Reactions Weekly, 2018, 1712 (1) : 397 - 397
[25] NivolumabImmune-mediated myositis: case report
Reactions Weekly, 2020, 1834 (1) : 208 - 208
[26] NivolumabImmune-mediated hepatitis: case report
Reactions Weekly, 2020, 1789 (1) : 195 - 195
[27] NivolumabImmune-mediated hypophysitis: case report
Reactions Weekly, 2022, 1908 (1) : 438 - 438
[28] NivolumabImmune-mediated diabetes mellitus: case report
Reactions Weekly, 2023, 1973 (1) : 227 - 227
[29] Cabozantinib/ipilimumab/nivolumabImmune-mediated enteritis, perianal abscess and perianal fistulas: case report
Reactions Weekly, 2025, 2043 (1) : 89 - 89
[30] Ipilimumab/NivolumabImmune-mediated hypophysitis and thyroid dysfunction: 2 case reports
Reactions Weekly, 2017, 1675 (1) : 138 - 138

← 1 2 3 4 5 →